CUE
Cue Biopharma
25.60$
+1.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -13.3% | -5.7% | +54.8% | +25.5% | -52.8% | -73.3% | +601.7% | -27.3% | +921.0% | -74.1% | +38.5% | – | |
| – | +50.3% | -93.7% | +1,022.5% | – | – | – | – | -21.0% | +3,958.2% | -97.6% | -53.2% | – | |
| – | – | – | +54.8% | +25.5% | -52.8% | -73.3% | +601.7% | -29.9% | +960.0% | -74.1% | +37.9% | – | |
| – | +10.3% | -6.3% | -6.6% | -1.6% | -23.4% | +19.0% | -7.5% | -40.8% | +252.8% | -58.3% | +610.6% | – | |
| – | +26.4% | -9.2% | -16.3% | -18.2% | +40.3% | +3.8% | -11.9% | +34.1% | -30.0% | +20.3% | +1,021.5% | – | |
| – | -52.3% | +564.1% | -9.3% | -6.8% | -7.8% | +13.5% | -8.9% | -17.0% | +107.9% | -44.7% | +765.0% | – | |
| – | – | – | – | – | – | – | – | – | – | -373.9% | – | – | |
| – | +77.3% | -52.5% | -10.8% | -12.6% | -18.6% | -16.3% | -64.8% | +66.7% | -32.0% | -92.2% | +25.0% | – | |
| – | – | – | – | – | – | – | – | – | – | -348.3% | – | – | |
| – | +15.3% | -0.2% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -426.7% | – | – | |
| – | – | – | – | – | – | – | – | – | – | -227.0% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.